Last A$0.05 AUD
Change Today -0.001 / -1.85%
Volume 10.6M
GTG On Other Exchanges
As of 11:56 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

genetic technologies ltd (GTG) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/19/15 - A$0.09
52 Week Low
12/16/14 - A$0.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

genetic technologies ltd (GTG) Related Bloomberg News

View More Bloomberg News

genetic technologies ltd (GTG) Related Businessweek News

No Related Businessweek News Found

genetic technologies ltd (GTG) Details

Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of genetic tests for breast and ovarian cancer, bowel and uterine cancer, and prostate cancer; neurogenetic diagnostic assays; and gene testing for Epilepsy SCN1A gene related disorders. The company also provides DNA based tests comprising peace of mind paternity, legal paternity, antenatal DNA, deceased estate, DNA profiling, grandparent, immigration, sibling, twins, and Y-chromosome DNA tests. In addition, it offers DNA testing, canine health register, forensics, and breed identification services to animals. Further, the company is involved in the out-licensing of its non-coding technology; and research and development activities in the field of genetics and related areas. Genetic Technologies Limited is headquartered in Fitzroy, Australia.

genetic technologies ltd (GTG) Top Compensated Officers

Chief Executive Officer, Chief Operating Offi...
Total Annual Compensation: A$14.4K
Director of Global Licensing & Intellectual P...
Total Annual Compensation: A$140.4K
Scientific Director
Total Annual Compensation: A$125.7K
Quality and Business Operations Director
Total Annual Compensation: A$98.7K
Compensation as of Fiscal Year 2014.

genetic technologies ltd (GTG) Key Developments

Genetic Technologies Limited Appoints Eutillio Buccilli as Chief Executive Officer

Genetic Technologies Limited announced that Mr. Eutillio Buccilli has been appointed Chief Executive Officer of the Company following the resignation of Ms. Alison Mew which was effective 31 December 2014. Mr. Buccilli joined the Company in June 2014 as the Chief Financial Officer and was appointed to the position of Chief Operating Officer and Chief Financial Officer in late 2014. He has more than 35 years of senior management experience in the financial services, contracting and recruitment, property and retail industries in Australia and the U.S. He has held senior management positions with General Electric, Computer Science Corporation, Coles Myer and Challenger Limited. Whilst at GE, Mr. Buccilli was seconded to the U.S., where he worked at the GE Capital Headquarters located in Stamford Connecticut.

Genetic Technologies Limited Announces 6 New Breast Centres to Begin Offering BREVAGenplus

Genetic Technologies Limited reported that up to 6 new breast diagnosis/treatment centres are expected to begin offering BREVAGenplus® to their at-risk patients in a systematic broad fashion in the January to March timeframe, with a growing number of additional new breast and imaging centre customers expected to follow later in calendar year 2015. As a result, the Company expects sales growth to accelerate in the second half 2015 and beyond. Prior to the release of BREVAGenplus, the Company revised its sales strategy to focus on large comprehensive breast treatment and imaging centres, in concert with its ongoing approach to independent physician and women’s healthcare providers. This recent pivotal change of sales and marketing emphasis towards large breast centres, which are more complex entities with a longer sales cycle, but with higher potential, is expected to lead to significant acceleration in growth and less volatile test volumes than the Company has experienced to date.

Genetic Technologies Limited Announces Findings from New BREVAGenplus Research Study

Genetic Technologies Limited announced that findings from a new research study show that adding a panel of 77 single-nucleotide polymorphisms (SNPs) improves the predictive accuracy of four commonly used breast cancer risk assessment models. This same panel of 77 SNPs is used in the Company's recently released BREVAGenplus, an easy-to-use predictive risk test for sporadic, or non-hereditary, breast cancer. Results were presented at the 2014 San Antonio Breast Cancer Symposium, on December 13, 2014. The study, entitled Value of Adding Single-Nucleotide Polymorphism Panel Markers to Phenotypic Algorithms of Breast Cancer Risk, was conducted under the supervision of Prof. John L. Hopper and first authored by Dr. Gillian S. Dite from the Centre for Molecular Epidemiology at the University of Melbourne. The study investigated the impact of adding the same 77 SNP panel used in BREVAGenplus to the following breast cancer prediction models: BOADICEA and BRCAPRO, both of which are based on pedigree data for breast and ovarian cancer; BCRAT (Gail score), which is based on established risk factors for breast cancer and family history as represented by the number of first-degree relatives with breast cancer; and IBIS, which combines information on both familial and personal risk factors for breast cancer. The researchers studied a population-based sample of 750 cases and 405 controls from the Australian Breast Cancer Family Registry and utilized the same methodology as a previous study of seven SNPs conducted by the same researchers. This new Australian study builds on previous observations that including information on multiple SNPs can improve the discriminatory accuracy of BCRAT risk assessment model (Mealiffe et al), as well as extending that observation to more recently identified SNPs associated with breast cancer. This study is expected to be published in a peer-reviewed scientific journal in early 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GTG:AU A$0.05 AUD -0.001

GTG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $42.21 USD -0.15
Sonic Healthcare Ltd A$19.44 AUD +0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation GTG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.2x
Price/Book 14.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENETIC TECHNOLOGIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at